Day Two: Wednesday March 8, 2017

REGISTRATION & COFFEE

8:00

Biomarkers & Companion Diagnostics

8:30

Integrating Rx and Dx in the era of personalized medicine



Jason Christiansen

Vice President, Diagnostics

Ignyta

9:00

Targeting a Drug Tolerant Cancer Cell Population Characterized by Heregulin Expression in Advanced Breast Cancer with Seribantumab

 

Greg Finn

Associate Director Clinical Development & Research

 

Merrimack Pharmaceuticals

9:30

Digital Pathology and Image Analysis in Breast Cancer

Rachel Skelton

Business Development Manager, Pharma Partnerships

Leica Biosystems

MORNING REFRESHMENTS & SPEED NETWORKING

10:00

10:30

Development of Circulating Tumor DNA Biomarkers

using Next Generation Sequencing

 

Ambar Ahmed

Translational Genomics Scientist

 

AstraZeneca

11:00

Title TBA: Liquid Biopsies: Changing Treatment Paradigms for Patients

 

 

Stefan Scherer

Vice President, Global Head Correlative Science

 

Novartis

11:30

Precision Medicine for Breast Cancers with Somatic HER2 Mutations

 

 

Alshad Lalani

Vice President, Translation Medicine and Diagnostics

 

Puma Biotechnology

12:00

Xtandi in patients with Triple Negative Breast Cancer; the journey of diagnostic development

 

Hirdesh Uppal

Head Companion Diagnostics & Translational Medicine


Medivation

PANEL DISCUSSION (TBA)

12:30

Participating:

Amir Handzel


Diagnostics and Personalized Medicine

AstraZeneca

Arnold Gelb

Head, Companion Diagnostic Development

EMD Serono

Hadrian Szpurka


Director, Clinical Diagnostics Laboratory

Eli Lilly

More to be announced..

1:00

1:20

Reveal ctDNA Focus Liquid Biopsy Panel for Breast Cancer.

 

Jill Stefanelli
Senior Director of Diagnostic Development, ArcherDx

Theranostic Target for the Development of Therapy with Companion Diagnostic in Oncology

 

Ginette Serrero
Chief Executive Officer, 
A&G Pharmaceutical

LUNCH & NETWORKING

1:35

Novel Approaches in Breast Cancer Drug R&D

2:00


Evaluation of novel endocrine agents in breast cancer trials.

 

Fiona Garner

Director of Oncology Research

 

Radius Health

2:30

A novel subgroup of ER positive breast cancer patients may benefit from super enhancer guided patient selection for RARa treatment

 

Emmanuelle diTomaso

Vice President, Translational Medicine

 

Syros Pharmaceuticals

3:00

BT1718, A Bicycle Drug Conjugate (BDC) Targeting MT1-MMP For The Treatment of Triple Negative Breast Cancer


Peter Park

Vice President, Oncology Research

Bicycle Therapeutics

3:30

Developing entinostat, a class 1 selective histone deacetylase inhibitor, in hormonal and immunological combinations for advanced breast cancer.

Peter Ordentlich

Chief Scientific Officer

Syndax

4:00

Tucatinib: Highly Selective Therapy for Her2+ Breast Cancer



Luke Walker

Vice President, Clinical Development

Cascadian Therapeutics

4:30

p53 modulation in Breast Cancer



Krishna Menon

Chief Scientific Officer

Cellceutix

SUMMARY & CLOSE OF CONFERENCE

5:00

VIEW PREVIOUS DAY

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2016 | All content produced by: neo-synth ltd.

Registration

Biomarkers & Companion Diagnostics

Integrating Rx and Dx in the era of personalized medicine



Jason Christiansen

Vice President, Diagnostics

Ignyta

Targeting a Drug Tolerant Cancer Cell Population Characterized by Heregulin Expression in Advanced Breast Cancer with Seribantumab

 

Greg Finn

Associate Director Clinical Development & Research

Merrimack Pharmaceuticals

Digital Pathology and Image Analysis in Breast Cancer

 

Rachel Skelton

Business Development Manager, Pharma Partnerships

Leica Biosystems

Networking Break

Development of Circulating Tumor DNA Biomarkers

using Next Generation Sequencing

 

Ambar Ahmed

Translational Genomics Scientist

 

AstraZeneca

Title TBA: Liquid Biopsies: Changing Treatment Paradigms for Patients

 

 

Stefan Scherer

Vice President, Global Head Correlative Science

 

Novartis

Precision Medicine for Breast Cancers with Somatic HER2 Mutations

 

 

Alshad Lalani

Vice President, Translation Medicine and Diagnostics

Puma Biotechnology

Xtandi in patients with Triple Negative Breast Cancer; the journey of diagnostic development

Hirdesh Uppal

 

Head Companion Diagnostics & Translational Medicine


Medivation

Panel Discussion

Reveal ctDNA Focus Liquid Biopsy Panel for Breast Cancer.

 

Jill Stefanelli
Senior Director of Diagnostic Development, ArcherDx

Theranostic Target for the Development of Therapy with Companion Diagnostic in Oncology

 

Ginette Serrero
Chief Executive Officer, 
A&G Pharmaceutical

Lunch

Novel Approaches


Evaluation of novel endocrine agents in breast cancer trials.

 

Fiona Garner

Director of Oncology Research

 

Radius Health

A novel subgroup of ER positive breast cancer patients may benefit from super enhancer guided patient selection for RARa treatment

 

Emmanuelle diTomaso

Vice President, Translational Medicine

Syros Pharmaceuticals

BT1718, A Bicycle Drug Conjugate (BDC) Targeting MT1-MMP For The Treatment of Triple Negative Breast Cancer


Peter Park

Vice President, Oncology Research

Bicycle Therapeutics

Developing entinostat, a class 1 selective histone deacetylase inhibitor, in hormonal and immunological combinations for advanced breast cancer.

Peter Ordentlich

Chief Scientific Officer

Syndax

Tucatinib: Highly Selective Therapy for Her2+ Breast Cancer



Luke Walker

Vice President, Clinical Development

Cascadian Rx

p53 modulation in Breast Cancer



Krishna Menon

Chief Scientific Officer

Cellceutix

Close of Event

DOWNLOAD GUIDE